<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0" nsmap="{'media': 'http://search.yahoo.com/mrss/'}"><channel><title>Raichur News Feed</title><link>https://news.google.com/rss/search?q=raichur&amp;hl=en-US&amp;gl=US&amp;ceid=US:en</link><description>Latest news about Raichur</description><language>en-US</language><item><title>USFDA concludes inspection at Shilpa Medicare Raichur unit</title><link>https://medicaldialogues.in/news/industry/pharma/usfda-concludes-inspection-at-shilpa-medicare-raichur-unit-144932</link><description>&lt;![CDATA[Karnataka: Shilpa Medicare has announced that the United States Food and Drug Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of the Company, located at Raichur.

The inspection was held from March 10-14, 2025.

The inspection was closed with ZERO observations.

This is second consecutive ZERO 483 inspection from USFDA at this site.

Read also: Shilpa Medicare Gets CDSCO Panel Nod for Novel NAFLD Drug, Advances to Mark...]]&gt;</description><pubDate>2025-03-15</pubDate><author>Ruchika Sharma, Written, Medically Reviewed, Dr. Kamal Kant Kohli</author><media:content url="https://medicaldialogues.in/h-upload/2023/01/10/197260-shilpa-medicare-2.jpg" medium="image" /></item></channel></rss>